The role of secondary cytoreductive surgery (SCS) in the treatment of recurrent ovarian cancer (ROC) has been widely increased in recent years, especially in trying to improve the quality of life of these patients by utilising a minimally-invasive (MI) approach. However, surgery in previously-treated patients may be challenging, and patient selection and surgical planning are crucial. Unfortunately, at the moment, validated criteria to select patients for MI-SCS are not reported, and no predictors of its feasibility are currently available, probably due to the vast heterogeneity of recurrence patterns. The aim of this narrative review is to describe the role of secondary cytoreductive surgery and, in particular, minimally-invasive procedures, in ROC, analyzing patient selection, outcomes, criticisms, and future perspectives.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571765PMC
http://dx.doi.org/10.3390/cancers15194769DOI Listing

Publication Analysis

Top Keywords

recurrent ovarian
8
ovarian cancer
8
role secondary
8
secondary cytoreductive
8
cytoreductive surgery
8
patient selection
8
minimally-invasive secondary
4
secondary cytoreduction
4
cytoreduction recurrent
4
cancer role
4

Similar Publications

Objective: To characterize the presentation and surgical management of ovarian fibromas among a case series of pediatric and adolescent patients with Gorlin syndrome.

Design: Retrospective case series.

Setting: Tertiary-care hospital.

View Article and Find Full Text PDF

Objective: To report a patient with McCune-Albright syndrome (MAS) with bilateral ovarian involvement who had achieved a pregnancy through in vitro fertilization (IVF).

Design: Case report.

Setting: Academic fertility center.

View Article and Find Full Text PDF

Malignant Brenner Tumor of the Ovary: A Critical Reappraisal.

Int J Gynecol Pathol

November 2024

Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia.

Malignant Brenner tumors (MBTs) are rare epithelial tumors of the ovary, most likely arising from benign and borderline Brenner tumors. MBTs may be misdiagnosed as other primary carcinomas or nonepithelial tumors of the ovary as well as metastatic carcinomas. Accurate diagnosis usually requires clinical-radiologic correlation, extensive sampling, and immunohistochemical studies.

View Article and Find Full Text PDF

Clinical implications of epithelial-to-mesenchymal transition in cancers which potentially spread to peritoneum.

Clin Transl Oncol

January 2025

Unit of Surgical Oncology, Department of Medicine Surgery and Neuroscience, University of Siena, Viale Mario Bracci 16, 53100, Siena, Italy.

Epithelial-to-mesenchymal transition (EMT) is a biological process by which epithelial cells increase their motility and acquire invasive capacity. It represents a crucial driver of cancer metastasis and peritoneal dissemination. EMT plasticity, with cells exhibiting hybrid epithelial/mesenchymal states, and its reverse process, mesenchymal-to-epithelial transition (MET), allows them to adapt to different microenvironments and evade therapeutic intervention.

View Article and Find Full Text PDF

Background: The benefit of cytoreduction with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for epithelial ovarian cancer (EOC) remains uncertain. This study investigated the relationship between serum cytokines, particularly monocyte chemoattractant protein-1 (MCP-1), a key inflammatory mediator, and recurrence risk in EOC patients undergoing CRS/HIPEC.

Methods: From January 2018 to January 2023, serum cytokine levels were analyzed in 34 EOC patients (17 primary, 17 recurrent) before and after CRS/HIPEC using MILLIPLEX Magnetic Bead Panels.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!